Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

BACKGROUND: Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here we describe a humanized antibody recognizing the RON plexin-semaphorin-integrin (PSI) domain with increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Xiang-Min, Feng, Liang, Suthe, Sreedhar Reddy, Weng, Tian-Hao, Hu, Chen-Yu, Liu, Yi-Zhi, Wu, Zhi-Gang, Wang, Ming-Hai, Yao, Hang-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743155/
https://www.ncbi.nlm.nih.gov/pubmed/31519211
http://dx.doi.org/10.1186/s40425-019-0732-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743155/
https://www.ncbi.nlm.nih.gov/pubmed/31519211
http://dx.doi.org/10.1186/s40425-019-0732-8

Ejemplares similares